bosentan anhydrous has been researched along with cycloheximide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fuhrmann, M; Juergens, LJ; Kämpfer, N; Racké, K; Schütz, I; Warnken, M | 1 |
| Babaahmadi-Rezaei, H; Dayati, P; Ghaffari, MA; Kamato, D; Little, PJ; Mohammad Zadeh, G; Sharifat, N | 1 |
2 other study(ies) available for bosentan anhydrous and cycloheximide
| Article | Year |
|---|---|
Endothelin-1 enhances β₂-adrenoceptor gene transcription in human lung fibroblasts.
Topics: Benzoxazines; Bosentan; Cell Line; Cycloheximide; Dactinomycin; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Fibroblasts; Humans; Polymerase Chain Reaction; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Adrenergic, beta-2; RNA, Messenger; Sulfonamides; Time Factors; Transcription, Genetic; Up-Regulation | 2012 |
Endothelin-1 (ET-1) stimulates carboxy terminal Smad2 phosphorylation in vascular endothelial cells by a mechanism dependent on ET receptors and de novo protein synthesis.
Topics: Animals; Benzamides; Bosentan; Cattle; Cycloheximide; Dioxoles; Endothelial Cells; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Phosphorylation; Protein Biosynthesis; Protein Synthesis Inhibitors; Receptor, Endothelin B; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Sulfonamides; Transforming Growth Factor beta | 2017 |